Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
45.61
-0.39 (-0.85%)
Mar 3, 2026, 11:29 AM EST - Market open
KNSA Revenue
In the year 2025, Kiniksa Pharmaceuticals International, had annual revenue of $677.56M with 60.09% growth. Kiniksa Pharmaceuticals International, had revenue of $202.13M in the quarter ending December 31, 2025, with 64.95% growth.
Revenue (ttm)
$677.56M
Revenue Growth
+60.09%
P/S Ratio
5.15
Revenue / Employee
$2,150,997
Employees
315
Market Cap
3.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 677.56M | 254.33M | 60.09% |
| Dec 31, 2024 | 423.24M | 152.98M | 56.60% |
| Dec 31, 2023 | 270.26M | 50.08M | 22.74% |
| Dec 31, 2022 | 220.18M | 181.64M | 471.24% |
| Dec 31, 2021 | 38.54M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Amneal Pharmaceuticals | 3.02B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
| Alkermes | 1.48B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| BioCryst Pharmaceuticals | 874.84M |
KNSA News
- 5 days ago - Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 7 days ago - Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution - GlobeNewsWire
- 11 days ago - Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 5 weeks ago - Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator - Seeking Alpha
- 7 weeks ago - Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Kiniksa Pharmaceuticals Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire